UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
October
2023
Commission
File Number: 001-41386
OKYO
Pharma LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th
Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
October 9, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing, that it has filed an Investigational New
Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain
(NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA., a copy of which is furnished as Exhibit
99.1
The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
OKYO
Pharma LTD |
|
|
|
Date:
October 9, 2023 |
By: |
/s/
Keeren Shah |
|
Name: |
Keeren
Shah |
|
Title: |
Chief
Financial Officer |
EXHIBIT
INDEX
Exhibit
99.1
![](https://www.sec.gov/Archives/edgar/data/1849296/000149315223036631/ex99-1_001.jpg)
OKYO
Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
● | OKYO
plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram
Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients
with NCP. |
● | Second
clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to
treat dry eye disease, with top-line data anticipated in December 2023. |
London
and New York, NY, October 9, 2023. OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative
therapies for the treatment of inflammatory dry eye disease (“DED”), a multi-billion-dollar market, and for neuropathic corneal
pain, a severe ocular condition with no FDA approved therapy, today announced that it filed an Investigational New Drug (IND) application
with the U.S. Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment
is planned to commence during Q1 2024 following IND allowance by the FDA.
NCP
remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the
opportunity to establish OK-101’s potential to treat this condition. The open-label trial will provide an opportunity to evaluate
the safety and efficacy of OK-101 for NCP in a real-world clinical setting, fostering a better understanding of its potential benefits
for patients.
The
NCP trial will be led by Pedram Hamrah, MD, Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service
and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist,
Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is a member of OKYO’s Scientific Advisory Board
and plans to serve as Principal Investigator of the study, which will be conducted at Tufts Medical Center.
“NCP,
which can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently
treated by various topical and systemic treatments in an off-label fashion,” said Dr. Hamrah. “However, there are no approved
commercial treatments currently available for this condition, and consequently we are looking forward to initiating the clinical trial
to investigate the potential efficacy of OK-101 to treat symptoms of NCP.”
“We
are excited about OK-101’s dual combination of anti-inflammatory ocular activity and NCP reducing activity and are eager to evaluate
this drug to treat NCP while awaiting the top-line data for OK-101 from the ongoing Phase 2 DED trial which is planned for released in
December 2023,” said Dr. Gary S. Jacob, CEO of OKYO.
About
OK-101
OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce
a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing
activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the
inclusion of the lipid ‘anchor’ contained in the drug molecule to enhance the residence time of OK-101 within the ocular
environment. OK-101 is currently in a Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.
About
the OK-101 Phase 2 DED Trial Design
This
phase 2, multi-center, randomized, double–blinded, placebo-controlled study is designed to enroll approximately 240 subjects with
DED who are being randomly divided into 3 cohorts of 80 patients. Participants are being selected based on specific inclusion and exclusion
criteria. The three cohorts include one cohort treated with placebo, a second cohort treated with 0.05% OK-101, and the third cohort
receiving 0.1% OK-101. The drug and placebo, respectively, are being administered in both eyes twice daily for 12 weeks. The duration
of a patient’s treatment is approximately 14 weeks, including a 2-week run-in period, to address the placebo effect, which is common
for trials involving a pain component, followed by 12 weeks of treatment. The protocol for the study includes two prespecified primary
endpoints and a number of secondary endpoints. Further details regarding the specifics of the trial are posted on the clinicaltrials.gov
public website (clinicaltrials.gov Identifier: NCT05759208 or https://clinicaltrials.gov/ct2/results?term=Okyo&cond=Dry+Eye+Syndromes).
About
OKYO
OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
DED) and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development
of novel molecules to treat inflammatory DED and ocular pain. OKYO presently has a 240-patient phase 2 trial of OK-101 underway to treat
patients with DED, and also has plans underway for the opening of a 40-patient trial of OK-101 to treat NCP in patients with this debilitating
condition. For further information, please visit www.okyopharma.com.
Forward-Looking
Statements
Certain
statements made in this announcement are forward-looking statements, including with respect to the anticipated timing of completion of
enrolment of the Company’s Phase 2 trial of topical ocular OK-101 to treat DED and the release of top-line data therefrom. These
forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and
projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’
‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties,
and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to
differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective
security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required
by law or by any appropriate regulatory authority.
For
further information, please visit the Company’s website at www.okyopharma.com
The person who arranged for the release
of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.
Enquiries:
OKYO
Pharma Limited |
Gary
S. Jacob, Chief Executive Officer |
U.S.
917-497-7560 |
|
|
|
Investor
Relations |
Paul
Spencer |
+44
(0)20 7495 2379 |
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
OKYO Pharma (NASDAQ:OKYO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024